SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is trending as community members express bullish sentiment and highlight its strong community-driven nature, referencing the revival of OG meme culture through rage comics. The community emphasizes building, conviction, and collaboration with other meme projects, while encouraging others to 'RAGE on' despite market conditions. Discussions also mention its branching out to other social platforms.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community discusses its potential integration with major payment systems and upcoming news. The ISO 20022 compliance and possible partnerships are key talking points, with some comparing it to early-stage XRP. Community members are actively strategizing on staking and accumulating more ZBCN.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet ($STRK) is trending as discussions revolve around its potential as a scaling solution for both Ethereum and Bitcoin, particularly with the recent advancements in BTCFi. Community members highlight its quantum-resistant technology and growing ecosystem, emphasizing its role in enabling privacy and scalability in decentralized finance. The focus is on staking and the potential for substantial returns.

English version Introducing SWFTCoin (SWFTC) $SWFTC: Powering SWFT Blockchain and AI Services (SWFTGPT)  SwftCoin ($SWFTC) is the native utility token driving SWFT Blockchain's AI-powered ecosystem, SWFTGPT, and the first ever AI token featured on Coinbase. SWFTGPT is also the first domain-specific LLM for crypto.  SwftCoin key features include: 50% Reduced Transaction Fees: Lower costs on all transactions. AI Service Payments: Use $SWFTC to access SWFTGPT. Tools include expert market analysis,  predictions, and intelligent trading solutions.  Membership Benefits: Unlock premium features and AI agent services within SWFTGPT. AI-Powered Swaps: Enable precise, fast cross-chain transactions and analytics. SWFT Blockchain combines AI innovation with blockchain infrastructure, simplifying crypto trading while enhancing functionality through $SWFTC.   Chinese version $SWFTC：驱动 SWFT Blockchain 和 AI 服务（SWFTGPT） SwftCoin ($SWFTC) 是 SWFT Blockchain 的原生实用代币，为其 AI 驱动的生态系统 SWFTGPT 提供支持，同时也是 Coinbase 上首个 AI 代币。SWFTGPT 也是首个专注于加密领域的特定领域大型语言模型 (LLM)。 SwftCoin 的主要功能包括： 1、50% 交易费减免：降低所有交易成本。 2、AI 服务支付：使用 $SWFTC 访问 SWFTGPT 工具，包括专家市场分析、预测以及智能交易解决方案。 3、会员权益：解锁 SWFTGPT 的高级功能和 AI 代理服务。 4、AI 驱动的闪兑：实现精准快速的跨链交易和数据分析。 SWFT Blockchain 将 AI 创新与区块链基础设施结合，通过 $SWFTC 简化加密交易，并提升其功能性。

SwftCoin

SwftCoin is trending as traders discuss its potential for a significant pump, with some noting its fully diluted status and others pointing to possible connections to the SWIFT banking system. Community members are actively debating entry points and long-term potential, while also speculating on possible exchange listings. Chatter includes bullish sentiment, mixed with caution around potential pump-and-dump schemes.

AlienBase

AlienBase ($ALB) is trending as community members discuss its potential, comparing it to Aerodrome ($AERO) while highlighting its smaller market cap and unique features like limit orders. Some users point to a potential Coinbase listing for Base network tokens, while others note its recent price movements and discuss optimal buying strategies. The conversation also includes discussions about staking rewards and the overall bullish sentiment surrounding the Base ecosystem.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is trending as community members discuss its potential for significant gains, drawing comparisons to Bitcoin and Zcash. Bullish sentiment is fueled by discussions around institutional adoption, ETF possibilities, and the anticipation of a potential 'alt season'. Traders are actively monitoring price movements, speculating on upcoming resistance breaks and potential for substantial upward momentum.

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita is trending amid discussions about its Q3 earnings, potential partnerships for innovative therapies like DefenCath, and the impact of new weight loss drugs on kidney disease. Community chatter also involves Berkshire Hathaway's large stake in the company and technical analysis suggesting possible bearish or reversal patterns. Some are highlighting concerns around mortality rates and the adoption of new technologies.

Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.

Evaxion A/S - ADR

Evaxion Biotech

EVAX is trending due to positive data for its AI-designed personalized cancer vaccine and a new CEO appointment expected to catalyze partnerships. The community speculates on potential deals before year-end, citing a consistent pattern observed in small-cap biotechs. Discussions also highlight the company's extended cash runway and expanding R&D pipeline.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending due to ongoing discussions about its financial performance and future prospects, especially surrounding the impact of TDAPA (Transitional Drug Add-on Payment Adjustment) on DefenCath sales. The community is focused on the company's growth rates, institutional ownership, and potential catalysts such as real-world evidence data and expansion into new markets, alongside external factors, including CMS (Centers for Medicare & Medicaid Services) decisions.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin ($XCN) is trending amid community discussions around potential pumps and dumps, as well as speculation regarding future price movements and Binance futures. Some traders are debating whether to hold or take profits, while others are pointing to the upcoming Goliath mainnet launch as a potential catalyst. Overall, the community's sentiment appears mixed, with some expressing frustration over recent performance, and others still hopeful for long-term gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

JPM downgrades Avis Budget after stock rally on recall, tariff impact

Investing.com -- JP Morgan downgraded  Avis Budget  (NASDAQ:CAR) Group to Neutral from Overweight, saying the stock’s sharp rally since March has outpaced the underlying earnings outlook, while near-term pressures from safety recalls and fading tariff tailwinds weigh on estimates.

These companies are most likely to surprise in real estate H1 earnings season

Investing.com -- Bernstein expects a mixed but potentially positive first-half earnings season for the European real estate sector, highlighting nine companies that could raise their guidance.

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference PR...

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference...

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline PR Newswire PHILADELPHIA, Dec. 9...

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting 2024

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting 2024 Carisma Therapeutics Presents Promising New...

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR...

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for...

Carisma Therapeutics Announces Changes to its Board of Directors

Carisma Therapeutics Announces Changes to its Board of Directors Carisma Therapeutics Announces Changes to its Board of Directors PR Newswire PHILADELPHIA, Oct. 30, 2024 Appointment of Sohanya Cheng...

Carisma Therapeutics Announces Upcoming Presentations at SITC 2024

Carisma Therapeutics Announces Upcoming Presentations at SITC 2024 Carisma Therapeutics Announces Upcoming Presentations at SITC 2024 PR Newswire PHILADELPHIA, Oct. 4, 2024 PHILADELPHIA, Oct. 4, 2024...

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.

CARM
Carisma Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CARM News

CARMCarisma Therapeutics Inc